KR102050700B1 - 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 - Google Patents

감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 Download PDF

Info

Publication number
KR102050700B1
KR102050700B1 KR1020197016572A KR20197016572A KR102050700B1 KR 102050700 B1 KR102050700 B1 KR 102050700B1 KR 1020197016572 A KR1020197016572 A KR 1020197016572A KR 20197016572 A KR20197016572 A KR 20197016572A KR 102050700 B1 KR102050700 B1 KR 102050700B1
Authority
KR
South Korea
Prior art keywords
inflammatory
compounds
disease
acid
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016572A
Other languages
English (en)
Korean (ko)
Other versions
KR20190069607A (ko
Inventor
엘. 잭슨 로버츠
벤카타라만 아마르나쓰
데이비드 쥐. 해리슨
키라보 아넷
Original Assignee
벤더르빌트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤더르빌트 유니버시티 filed Critical 벤더르빌트 유니버시티
Publication of KR20190069607A publication Critical patent/KR20190069607A/ko
Application granted granted Critical
Publication of KR102050700B1 publication Critical patent/KR102050700B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020197016572A 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 Active KR102050700B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
US61/506,848 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147003650A Division KR20140050661A (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법

Publications (2)

Publication Number Publication Date
KR20190069607A KR20190069607A (ko) 2019-06-19
KR102050700B1 true KR102050700B1 (ko) 2019-11-29

Family

ID=47506934

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197016572A Active KR102050700B1 (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법
KR1020147003650A Ceased KR20140050661A (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147003650A Ceased KR20140050661A (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법

Country Status (13)

Country Link
US (4) US10975033B2 (https=)
EP (1) EP2731597B1 (https=)
JP (1) JP6280033B2 (https=)
KR (2) KR102050700B1 (https=)
CN (2) CN103796648B (https=)
AU (1) AU2012281061B2 (https=)
BR (1) BR112014000810A8 (https=)
CA (1) CA2844150C (https=)
ES (1) ES2970814T3 (https=)
HU (1) HUE065757T2 (https=)
MX (1) MX383365B (https=)
PL (1) PL2731597T3 (https=)
WO (1) WO2013010034A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US11400103B2 (en) 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US10166248B1 (en) 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
AU2017293846B2 (en) * 2016-07-06 2022-03-17 Vanderbilt University Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan
CN110022936A (zh) * 2016-07-07 2019-07-16 范德比尔特大学 用γ-酮醛清除剂预防和治疗心房颤动/扑动
EP3510014B1 (en) * 2016-09-06 2026-04-29 Metabolic Technologies, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald
WO2018048937A1 (en) * 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
PL3541185T3 (pl) * 2016-11-15 2024-08-12 Vanderbilt University Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu
US11389414B2 (en) 2017-04-27 2022-07-19 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
AU2018330416B2 (en) * 2017-09-05 2024-09-26 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
JP2023512225A (ja) * 2020-01-27 2023-03-24 ヴァンダービルト ユニバーシティー ミトコンドリア標的イソケタール／イソレブグランジンスカベンジャー及びその使用
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) * 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
CA2219944A1 (en) 1995-05-19 1996-11-21 Miho Kobayashi 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1341532B1 (en) 2000-11-02 2006-07-26 University of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
JP5547637B2 (ja) * 2007-10-05 2014-07-16 インデックス・ファーマシューティカルズ・アクチエボラーグ 浮腫を治療または軽減するための新規な化合物およびその使用方法
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
HUE065757T2 (hu) 2024-06-28
US20250034093A1 (en) 2025-01-30
US20250214939A1 (en) 2025-07-03
MX383365B (es) 2025-03-13
JP6280033B2 (ja) 2018-02-14
ES2970814T3 (es) 2024-05-30
WO2013010034A2 (en) 2013-01-17
US20210261508A1 (en) 2021-08-26
EP2731597C0 (en) 2023-12-20
CA2844150C (en) 2019-09-03
JP2014524918A (ja) 2014-09-25
CA2844150A1 (en) 2013-01-17
CN111494352A (zh) 2020-08-07
MX2014000515A (es) 2014-03-27
US10975033B2 (en) 2021-04-13
EP2731597A4 (en) 2015-04-08
EP2731597B1 (en) 2023-12-20
EP2731597A2 (en) 2014-05-21
WO2013010034A3 (en) 2013-03-28
AU2012281061B2 (en) 2017-08-03
KR20190069607A (ko) 2019-06-19
PL2731597T3 (pl) 2024-04-29
CN103796648B (zh) 2019-10-25
KR20140050661A (ko) 2014-04-29
CN103796648A (zh) 2014-05-14
BR112014000810A2 (pt) 2017-06-13
US20140256774A1 (en) 2014-09-11
AU2012281061A1 (en) 2014-02-20
BR112014000810A8 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
KR102050700B1 (ko) 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법
ES3058507T3 (en) Novel uses of piperidinyl-indole derivatives
Zhao et al. Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model
US9603869B2 (en) Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
CN106456606A (zh) 吲哚基及吲哚啉基异羟肟酸于治疗神经退化病症或认知缺乏的用途
JP2013530159A (ja) ホオズキ抽出物を有効成分として含有する炎症性疾患の予防及び治療用組成物
JP6814240B2 (ja) クルクミン誘導体の使用
US20230355549A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
HK40023703A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
CN102905701A (zh) 用于治疗朊病毒病的1-(2-氟联苯-4-基)-环丙烷羧酸衍生物
US20220347163A1 (en) Compositions and methods for providing cardioprotective effects
KR20250111125A (ko) mTORC1 활성의 조절제 및 이의 용도
Habib Therapeutic Modulation of Alzheimer's Disease with Biological (HUCBS) and Pharmacological (LISPRO) Approaches
JP2006282639A (ja) プロスタグランジン産生阻害剤及び抗炎症剤
Tan et al. Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
HK1191859A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
Clarkson Secondary Cardiovascular Abnormalities Subsequent to Cerebral Hypoxia-Ischaemia
Clarkson Cardiovascular Abnormalities as a Consequence of Cerebral Hypoxia-Ischaemia
HK1180948A (en) 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190610

Application number text: 1020147003650

Filing date: 20140212

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191008

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221108

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241107

Start annual number: 6

End annual number: 6